Indivior Pharmaceuticals Inc (INDV) Revenue History
Annual and quarterly revenue from 2016 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
INDV Revenue Growth
Revenue Breakdown (FY 2025)
INDV's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
INDV Revenue Analysis (2016–2025)
As of May 8, 2026, Indivior Pharmaceuticals Inc (INDV) generated trailing twelve-month (TTM) revenue of $1.29 billion, reflecting strong growth of +19.2% year-over-year. The most recent quarter (Q1 2026) recorded $317.0 million in revenue, down 11.5% sequentially.
Looking at the longer-term picture, INDV's 5-year compound annual growth rate (CAGR) stands at +13.9%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $1.24 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows INDV's business is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including RBBN (-1.2% YoY), AVPT (+27.1% YoY), and ALKS (+3.2% YoY), INDV has underperformed the peer group in terms of revenue growth. Compare INDV vs RBBN →
INDV Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| INDVCurrent | $1.3B | +19.2% | +13.9% | 21.4% | |
 RBBN | $845M | -1.2% | +0.0% | 2.4% | |
 AVPT | $419M | +27.1% | +22.6% | 7.9% | |
 ALKS | $1.5B | +3.2% | +7.3% | 17.2% | |
 BHC | $10.4B | +8.5% | +5.4% | 21.3% |
INDV Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.24B | +4.3% | $993.0M | 80.1% | $265.0M | 21.4% |
| 2024 | $1.19B | +8.7% | $957.0M | 80.6% | $32.0M | 2.7% |
| 2023 | $1.09B | +21.3% | $919.0M | 84.1% | $-156,000,000 | -14.3% |
| 2022 | $901.0M | +13.9% | $750.0M | 83.2% | $-81,000,000 | -9.0% |
| 2021 | $791.0M | +22.3% | $664.0M | 83.9% | $213.0M | 26.9% |
| 2020 | $647.0M | -17.6% | $550.0M | 85.0% | $-156,000,000 | -24.1% |
| 2019 | $785.0M | -18.2% | $645.0M | 82.2% | $178.0M | 22.7% |
| 2018 | $959.9M | -16.4% | $825.2M | 86.0% | $317.1M | 33.0% |
| 2017 | $1.15B | +18.5% | $1.03B | 89.3% | $423.3M | 36.9% |
| 2016 | $968.9M | - | $858.1M | 88.6% | $337.9M | 34.9% |
See INDV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INDV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare INDV vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonINDV — Frequently Asked Questions
Quick answers to the most common questions about buying INDV stock.
Is INDV's revenue growth accelerating or slowing?
INDV revenue is accelerating at +19.2% year-over-year, exceeding the 5-year CAGR of +13.9%. TTM revenue reached $1.3B. Growth momentum has increased versus prior periods.
What is INDV's long-term revenue growth rate?
Indivior Pharmaceuticals Inc's 5-year revenue CAGR of +13.9% reflects the sustained expansion pattern. Current YoY growth of +19.2% is above this long-term average.
How is INDV's revenue distributed by segment?
INDV reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2025 are available for download. Segment mix reveals concentration and diversification trends.